quality control review & editing services
Delivering an unparalleled attention to detail
Detailed and comprehensive quality control (QC) reviews (or data verification reviews) and editing are an integral part of the production lifecycle of a document, rather than a one-off step in the development process. Mistakes and inconsistencies in a document can call into question the validity of the content or result in an incorrect interpretation of the data.
ProPharma’s team of seasoned QC reviewers/editors provides quality review and editing services across a wide array of documents and therapeutic areas.
Ready to Speak to a Quality Control Reviewer/Editor?
Quality Control Review/Editing Services
ProPharma QC reviewers/editors perform targeted or comprehensive quality control reviews of documents to ensure accuracy, integrity, and consistency of both data and messaging.
Quality control reviews and/or editorial reviews are performed on any deliverable, in any therapeutic area, using either client checklists or our internal document-specific checklists to ensure the quality and consistency both within and across documents.
Quality Control Review:
Data Verification
ProPharma QC reviewers/editors provide 100% source verification of all data in both document text and in-text tables, as necessary. Data verification review is offered in addition to editorial review or as a standalone service.
Editorial Review:
No Data Verification
ProPharma QC reviewers/editors provide a complete editorial review to ensure consistency, clarity of message, and appropriate implementation of style and template requirements. Editorial review includes general copy editing and review of abbreviations, internal cross references, and citations, and is offered in addition to data verification review or as a standalone service.
Benefits of Working with Our Quality Control Review/Editing Team
GLOBAL AND EXPERIENCED
ProPharma QC reviewers/editors are located across North America, Europe, and India. They have an average of 10 years of experience spanning multiple therapy areas and domains.
FLEXIBLE AND SCALABLE
With access to a large pool of experienced resources, we are responsive to changes in workload and can scale as needed to accommodate variable client demands and volume.
COMPREHENSIVE AND THOROUGH
We perform comprehensive reviews of each document using detailed document-specific checklists to ensure quality and consistency within and across documents.
Quality Control Review Frequently Asked Questions
Click on frequently asked questions about ProPharma's quality control review and editing services to learn about our experience and expertise.
Yes, ProPharma QC reviewers/editors accommodate last-minute and drop-in QC requests as needed.
ProPharma understands that timelines shift, projects get cancelled, and that shifting timelines are a potential risk in any project. ProPharma remains flexible and mitigates this risk through consistent project and resource management. Resource availability and project status are routinely reviewed and updated, allowing us to adapt in real time and overcome any potential challenges, including timeline shifts.
If a project shifts out significantly, we work with clients to map out a plan that ensures both timely delivery and service continuity. We take steps to ensure (to the extent possible) the same person can re-engage on the project once it becomes active again. If timelines accelerate, we can provide additional resources, as needed, to ensure timeline integrity.
ProPharma can utilize either our internal QC SOPs or client SOPs.
Yes. ProPharma has both general and document-specific QC checklists.
Yes, ProPharma QC reviewers/editors provide consistent application of general and/or client-specific style guides (including therapeutic area-specific style guides, as applicable).
Have questions? We'd be happy to talk with you
about your unique needs and goals.
News & Insights
October 23, 2025
How Mature Is Your Data Integrity? New FDA and EU Regulatory Focus Areas
Explore the evolving regulatory landscape in data integrity with FDA and EU 2025 updates, focusing on digital systems, AI, and stringent compliance measures.
October 16, 2025
The Shift Toward Globalization in Medical Information: How ProPharma is Helping ...
ProPharma enhances globalization in Medical Information services, offering tailored solutions in Japan that balance global standards with local regulatory and cultural demands.
July 8, 2025
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
October 30, 2025
Improving Patient Health and Safety through Pharmacovigilance and Medical Inform...
In today’s data-driven pharmaceutical landscape, patient safety depends on more than vigilance — it demands collaboration. Pharmacovigilance and Medical Information teams are no longer operating in...
October 29, 2025
CMC Management and Execution
Global regulatory demands on Chemistry, Manufacturing, and Controls (CMC) are intensifying—spanning pharmaceuticals, biologics, and combination products. From tech transfers to lifecycle management,...
October 6, 2025
Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...
When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, ProPharma stepped in —...
November 18, 2025
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions
Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...
November 11, 2025
Tips for Successful MAA Submissions in Europe
Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...
News & Insights
October 30, 2025
Improving Patient Health and Safety through Pharmacovigilance and Medical Inform...
In today’s data-driven pharmaceutical landscape, patient safety depends on more than vigilance — it demands collaboration. Pharmacovigilance and Medical Information teams are no longer operating in...
October 6, 2025
Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...
When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, ProPharma stepped in —...
November 18, 2025
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions
Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...